Glycemic Control Tied to Better Outcome of Anti-VEGF Therapy for Diabetic Macular Edema
02/08/2019
Strong glycemic control may optimize vision outcomes in patients with diabetic macular edema (DME) treated with anti-vascular endothelial growth factor (anti-VEGF) therapy, researchers say, according to a Reuters report.
Dr. Jennifer Sun, chair of Diabetes Initiatives for the Diabetic Retinopathy Clinical Research (DRCR) Network, and colleagues conducted a post hoc analysis of the network’s multicenter randomized clinical trial Protocol T, which compared three commonly used anti-VEGF agents in patients with central-involved DME and vision impairment (20/32 or worse).